Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral ...

Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not ...

A study published in 2016 raised concerns that patients with liver cancer related to hepatitis C virus (HCV) may have a higher risk for recurrence if they are treated with direct-acting antiviral (DAA ...

Introduction: Data on the risk of hepatocellular carcinoma (HCC) recurrence in a transplanted liver following direct‑acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection are sparse and ...

Credit: Shutterstock. Direct-acting antiviral therapy is not associated with increased overall or early hepatocellular carcinoma recurrence among patients with a previous complete response to HCC ...

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School ...